2024
Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting
Hofmeister C, Zhang M, Gupta V, Joseph N, Kaufman J, Nooka A, Dhodapkar M, Lonial S, Sborov D. Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting. Blood 2024, 144: 5152-5152. DOI: 10.1182/blood-2024-202100.Peer-Reviewed Original ResearchNon-Hispanic blacksNon-Hispanic whitesSurveillance Epidemiology and End ResultsNational Cancer InstituteWhite patientsBlack menBlack patientsAvailability of diagnosisWhite menStudy start dateEncounter dateSEER dataFace-to-faceHealth systemMultiple myeloma patientsMyeloma patientsOutpatient encountersDeath reportingAge decileSocial Vulnerability IndexWhite womenMatched control groupBlack womenMedian survivalPatient recordsA Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma
Hofmeister C, Gupta V, Kaufman J, Nooka A, Joseph N, Lonial S, Dhodapkar M. A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma. Blood 2024, 144: 255-255. DOI: 10.1182/blood-2024-202102.Peer-Reviewed Original ResearchPlasma cell disorderStandard armInfluenza vaccineMyeloma patientsIntensive armDaratumumab exposureRandomized controlled trialsMultiple myelomaFlu seasonCell disordersHistory of severe allergic reactionsStandard-dose influenza vaccinesTreat analysisRisk of influenza-like illnessT-cell engagersSeasonal influenza vaccineHigh dose vaccineHigh dose injectionsInfluenza-like illnessProportion of patientsFlu vaccinationVaccine preventable illnessYears of ageSevere allergic reactionsStatistically significant difference
2023
Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)
Joseph N, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Boise L, Lonial S, Nooka A. Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD). Blood 2023, 142: 647. DOI: 10.1182/blood-2023-187339.Peer-Reviewed Original ResearchStandard-risk patientsHigh-risk patientsOverall response rateRisk patientsPFS benefitInduction therapyHR patientsInduction regimenMyeloma patientsNDMM patientsTransplant-eligible multiple myeloma patientsInternational Myeloma Working Group Uniform Response CriteriaHigh-risk MM patientsEffective induction regimenHigh-risk cytogeneticsCombination of lenalidomideHigh-risk diseaseMultiple myeloma patientsUniform response criteriaDepth of responseLong-term outcomesEvidence of benefitMaintenance therapyOS benefitClinical characteristicsEfficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma
Kaufman J, Joseph N, Gupta V, Dicamillo S, Roberts D, Hofmeister C, Dhodapkar M, Nooka A, Lonial S, Boise L. Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma. Blood 2023, 142: 4699. DOI: 10.1182/blood-2023-181783.Peer-Reviewed Original ResearchStandard-risk patientsVGPR ratesRisk patientsPart of inductionInduction therapyMyeloma patientsNDMM patientsInternational Myeloma Working Group Uniform Response CriteriaStage 3 patientsCombination of lenalidomideHigh-risk patientsPhase 3 studyCohort of patientsUniform response criteriaDistinct clinical presentationsFree light chainsInstitutional review boardLenalidomide maintenanceMedian OSMedian PFSRVD inductionLast followClinical characteristicsOverall survivalPatient characteristics